Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
Medifast, Inc. (MED) Q1 2026 Earnings Call Transcript
Medifast (MED) Reports Q1 Loss, Tops Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.11 per share a year ago.
Medifast's Q1 Earnings on The Horizon: Key Insights for Investors
MED reports Q1 fiscal 2026 May 4; revenue seen down 36.3% and EPS at a 55-cent loss as coach base and demand stay pressured.
Medifast's New Product Pipeline: Key Catalyst for Comeback?
MED's science-led metabolic health push and new product pipeline could spark a turnaround as it targets GLP-1 transition users and profitability growth.
Medifast (MED) Down 5.7% Since Last Earnings Report: Can It Rebound?
Medifast (MED) reported earnings 30 days ago. What's next for the stock?
Medifast Q4 Loss Wider Than Expected, Revenues Decline 37% Y/Y
MED posts a wider quarterly loss as revenue tumbles 36.9% on a sharp drop in OPTAVIA coaches, despite beating revenue estimates.
Medifast (MED) Reports Q4 Loss, Beats Revenue Estimates
Medifast (MED) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to earnings of $0.1 per share a year ago.
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Medifast's Q4 Earnings on Deck: What Could Shape MED's Results?
MED is likely to post a sharp Q4 revenue drop and a wider loss as active earning coaches decline and GLP-1 pressure weighs despite retention and pricing efforts.
Analysts Estimate Medifast (MED) to Report a Decline in Earnings: What to Look Out for
Medifast (MED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medifast Is A Net-Net With Negative Enterprise Value
Medifast trades below net cash, with an EV of -$43.68M, reflecting deep skepticism about its OPTAVIA MLM business and turnaround prospects. GLP-1 drugs have rendered MED's weight-loss model largely obsolete, prompting a pivot toward metabolic health services, though execution risk remains high. Despite ongoing losses, MED's cash burn is modest; even with conservative assumptions, shares likely remain a net-net with limited downside over the next year.
Medifast's Q4 Guidance Remains Weak: When Does Growth Return?
MED sees weak Q4 guidance after steep revenue declines, but a metabolic health pivot targets stabilization and recovery.
